Stem cell therapies - K-STEMCELL

Drug Profile

Stem cell therapies - K-STEMCELL

Alternative Names: Adipose stem cell therapies - K-STEMCELL; Adult-derived stem cell therapies - K-STEMCELL; Astrostem; Autologous adipose stem cells - K-STEMCELL; Autologous Adipose Tissue derived MSCs Transplantation - K-STEMCELL; Cancerstem; Fat-derived stem cell therapies - K-STEMCELL; JointStem; Lipostem-DM; Lipostem-Femoran; Mesenchymal stem cell therapies - K-STEMCELL; RNL-JointStem; RNL-Vascostem; Vascostem

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RNL BIO
  • Developer Asan Medical Center; K-STEMCELL; Nature cell
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Osteoarthritis
  • Phase II Alzheimer's disease
  • Phase I/II Femur head necrosis; Intervertebral disc degeneration; Spinal cord injuries; Thromboangiitis obliterans
  • Preclinical Cancer; Cerebral infarction; Diabetes mellitus; Fracture; Ischaemic heart disorders
  • No development reported Facial hemiatrophy; Liver disorders; Peripheral vascular disorders

Most Recent Events

  • 10 Mar 2017 Phase-I clinical trials in Alzheimer's disease in USA (IV)
  • 10 Mar 2017 Phase-II clinical trials in Alzheimer's disease in USA (IV)
  • 01 Dec 2016 Biostar completes a phase II/III trial in Osteoarthritis in South Korea (Intra-articular) (NCT02658344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top